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Introduction
As the population ages, the number of patients suffering from chronic wounds attributable 
to diseases such as diabetes mellitus and peripheral vascular disease is on the rise. This 
poses a significant impact on the health care system, because of the chronicity of care 
required and the associated costs. A chronic wound does not progress through the four 
overlapping phases of wound healing. Instead, it is commonly arrested at the inflammatory 
phase, due to the presence of slough, necrotic debris and infection. Traditionally, the 
principles of treatment for acute and chronic wounds include debridement and the 
application of dressings. Wound debridement involves removing necrotic tissue, exudates, 
foreign material and bacteria, so that the normal stages of wound healing can take place. 
The use of dressing materials prevents local contamination of the wound site, facilitates 
exudate removal, and prevents infection.1 In addition, much research has been devoted 
to developing new techniques to enhance and hasten the process of wound healing, 
including adjuvant growth factors, tissue-engineered products, hyperbaric oxygen and 
negative pressure wound therapy.1,2 As an alternative to surgery, maggot debridement 
therapy (MDT) has been shown to provide rapid and effective wound debridement, thus 
hastening the process of wound healing and lowering the overall costs of management.3-7
Historical perspective
The utilisation of larvae for wound healing has been well-documented across the centuries 
in different cultures, including the Chinese. The beneficial effects of using larvae in 
wounds were first noticed by Ambrose Paré in 1557.8,9 While treating battle wounds in 
Napoleon’s army, Baron Larrey observed that maggots enhanced granulation formation.10 
The first clinical application of maggot therapy was performed by JF Zacharias and J Jones 
during the American Civil War.11 Later, William Baer refined the technique by using sterile 
maggots to prevent maggot-induced wound infection. The therapy became increasingly 
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more popular and was widely used for the treatment 
of chronic or infected wounds across North America 
and Europe during the 1930s. With the introduction 
and the widespread use of antibiotics in the 1940s, 
the popularity of MDT gradually declined and 
became largely forgotten by the medical community. 
However, with the rising incidence of antibiotic 
resistance in the late 1990s, there is renewed interest 
in maggots and their potential use in chronic wound 
management.11,12
The larvae—green-bottle fly Lucilia 
(Phaenicia) sericata
The larvae of the green-bottle fly Lucilia (Phaenicia) 
sericata are the most commonly used for wound 
management. This fly belongs to the Diptera order 
of insects, which are known to be able to infest 
living hosts and parasitise host tissue. The 1-2 mm 
long larvae hatch from their eggs in 12 to 24 hours.13 
Feeding on necrotic tissue in the moist environments 
of wounds, they grow rapidly and mature in 4 to 5 
days, measuring around 10 mm in length. Later they 
pupate and become adult flies.13
Maggot debridement therapy
Larvae used for MDT need to be sterile to prevent 
contamination, and therefore must be bred in a 
controlled sterile, moist environment.7,13 Newborn 
larvae should be used within 8 hours or stored 
in a refrigerator at 8º to 10ºC, so as to slow their 
metabolism.7 To maximise debridement, it is 
important to ensure an optimal body temperature, 
adequate oxygen supply and moisture, though too 
much moisture may kill the larvae.2,13 The use of 
occlusive dressings should be avoided, as larvae 
require oxygen to survive.13 Propylene glycol from 
hydrogel dressings can limit the growth and viability 
of larvae, while systemic antibiotics do not affect 
larval development.13
Mechanisms of maggot debridement 
therapy
Debridement
Scientists first postulated that the debriding action 
of maggots was due to their mechanical wriggling.14 
Maggots use a pair of mandibles/hooks for 
movement and attachment, and it was believed that 
the probing from the hooks may facilitate wound 
debridement. Recently, three proteolytic enzyme 
classes have been identified in the maggot excretions/
secretions (ES).15 These enzymes effectively degrade 
extracellular matrix components, including laminin 
and fibronectin. The ES could thus assist in the 
digestion of the wound matrix, leading to effective 
debridement.
Disinfection
The presence of antibacterial substances has long 
been identified in maggot ES. Thus, ES has an inhibitory 
effect on Gram-positive and Gram-negative bacteria, 
including methicillin-sensitive Staphylococcus aureus, 
methicillin-resistant S aureus (MRSA), Escherichia 
coli and Pseudomonas aeruginosa.16 This activity of 
the ES was thermally stable and protease-resistant. 
Using ultrafiltration, the latter study identified two 
fractions with inhibitory effects on S aureus and 
MRSA. It was also believed that ammonia excreted 
by maggots increases wound pH, thereby creating an 
unfavourable environment for bacterial growth.17
 According to another hypothesis, maggots 
ingest bacteria and kill them within their alimentary 
tract. Mumcuoglu et al18 investigated the fate of E 
coli after ingestion by L sericata. It transpired that the 
proximal alimentary canal was more heavily infested, 
with 67% of the throat harbouring live bacteria. The 
figures dropped dramatically as the bacteria moved 
distally along their alimentary canal. Only 18% of the 
posterior hindgut was found to contain live bacteria.
Enhancement of wound healing
It was believed that the enhancement in tissue growth 
was due to an increase in fibroblast proliferation 
brought about by the ES.19 Horobin et al20 demon-
strated that the ES altered fibroblast adhesions to 
collagen and fibronectin, and it was subsequently 
shown that it increased the migration (but not 
proliferation) of fibroblasts. This was attributed mainly 
to the action of serine and metallo proteinases. These 
		#		Chan	et	al	#
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investigators then developed a three-dimensional 
model to better simulate a human wound.21 Their 
results were consistent with the previous studies and 
supported by later investigators.22 An upregulation of 
tyrosine phosphorylation was also detected, which 
possibly enhanced the motility of the fibroblasts.22 
Others have postulated that maggots secreted 
cytokines, which help wound healing. High levels 
of gamma-interferon and interleukin-10 (IL-10) were 
found in the ES, but as to whether these cytokines 
are responsible for increasing granulation requires 
further investigation.19
Indications for maggot debridement 
therapy
Maggot debridement therapy is mainly used for the 
cleaning and disinfection of chronic wounds that 
are sloughy, necrotic, and infected. Various clinical 
studies have demonstrated the efficacy of MDT in 
treating wounds that fail to heal following alternative 
forms of treatment. Wollina et al4 demonstrated that 
MDT could rapidly reduce a mean±standard deviation 
wound score of 13.5±1.8 to 6.3±2.7 (P<0.001) with only 
a single application of maggots for 1 to 4 days. The 
wound score was determined by and proportional to 
slough coverage, exudation, malodour, granulation 
and inflammation of surrounding skin. Larvae were 
effective in removing necrotic tissue and exudation 
without damaging adjacent healthy tissue. This action 
stimulated tissue granulation and reduced offensive 
odours brought about by infections.
 The benefits of MDT have been reported for 
a variety of chronic wounds (Box3,4,12,13,23-40). With 
the emergence of antibiotic resistance, MDT has 
been demonstrated to be useful in surgical wounds 
infected with MRSA.12,40 Compared to conventional 
hydrogel therapy, MDT was more effective for 
chronic venous ulcers, diabetic ulcers, and pressure 
ulcers.23-25 In a controlled study on diabetic foot 
ulcers, 14 patients were randomly allocated to 
receive MDT and another 14 to conventional therapy. 
There was no significant debridement after 14 days 
in the conventional therapy group. Whereas, after 
14 days there was a mean decrease in necrotic tissue 
of 4.1 cm2 (P=0.02) in the MDT group, and complete 
debridement was achieved in 4 weeks.25 In another 
study on venous ulcers, 12 patients were randomised 
to receive MDT or conventional therapy. Complete 
debridement was achieved in the MDT group with 
one application for 3 days, while only two out of six 
patients in the conventional therapy group achieved 
complete debridement after 1 month. The other four 
patients required repeated changes of dressing.23 As 
for pressure ulcers, a study was performed with 103 
patients randomly assigned to MDT or conventional 
therapy; 80% of patients in the MDT group achieved 
complete debridement within 5 weeks, while only 
48% did so after conventional treatment (P=0.021).24
Contra-indications and side-effects
Dry wounds are a relative contra-indication as 
maggots require a moist environment. The use of 
maggots should also be avoided in open wounds of 
body cavities or wounds in close proximity to large 
blood vessels so as to facilitate the removal of the 
larvae.7 Also, maggots should not be used in patients 
who are allergic to eggs, soybeans, or fly larvae.41
 Maggot debridement therapy has not 
been associated with major adverse effects or 
complications, but has been reported to cause mild 
discomfort, malodour at the first change of dressing, 
and escape of larvae.13 Excessive pressure applied on 
to parts of the wound may also kill maggots in that 
area, leading to uneven wound debridement. Despite 
these shortcomings, even patients experiencing 
pain during treatment tend to report improved 
appearance.6 Five bloodstream infections attributed 
to contaminated larvae of Protophormia terraenovae 
have been reported, but provided that the maggots 
have been effectively disinfected, their use on chronic 
ulcers appears to be safe.42
 A major obstacle to the utilisation of MDT 
appears to be its poor acceptance by both patients 
and health care professionals. Social and cultural 
beliefs and the so-called ‘yuk’ factor may initially 
hinder its use, but studies have shown that patients 
who receive adequate psychological preparation and 
relevant information from health care professionals 
are more likely to accept the initial therapy and further 
treatments.7 Thus, experience of MDT tends to be less 
‘frightening’ and more beneficial than imagined. It is 
BOX.  Types of wounds/lesions for which maggot therapy may 
be used
Diabetic ulcers4,13,25-27
Venous ulcers4,23,27
Neuropathic ulcers (non-diabetic ulcers)4,13
Arterial/ischaemic ulcers4,13,28
Pressure sores3,24,28
Thromboangiitis obliterans4,13,27
Post-traumatic wounds/ulcers3,13,28-30
Necrotising fasciitis31-33
Pyoderma gangrenosum4,13
Excised abscess on malleolus3
Pilonidal sinus3
Grossly infected toe3
Osteomyelitis27,34
Infected wound after forearm replantation35
Wound of exposed knee prostheses36
Wound infection after breast surgery30
Infected gun shot wound27
Malignant wounds4,37
Burns28,38
Non-healing surgical wound28,40
Methicillin-resistant Staphylococcus aureus–infected 
wound12
Mixed arterial-venous ulcer4
Subacute mastoiditis39
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nevertheless important that health care professionals 
address and attempt to alleviate patient concerns and 
respect their wishes at all times.
Is maggot debridement therapy cost-
effective?
Waymen et al23 demonstrated the cost-effectiveness 
of MDT in patients with chronic venous ulcers. In 
their study, the median cost of treatment per patient 
in the larval group was £79 compared to £136 for the 
hydrogel controls (P<0.05). The MDT group required 
fewer visits to achieve debridement than the controls 
(median number of visits: 3 vs 19; P<0.05). According 
to Thomas and Jones,3 when nursing costs were 
included, the total expenditure on materials to 
successfully debride one wound was £82 versus £503, 
in favour of MDT. The reduction in total costs could 
be attributed to reduced debridement times as well 
as reduced number of hospital visits or bed days, all 
of which resulted in significant savings for the health 
care system.
The future for maggot debridement 
therapy—a new delivery system
Studies have shown that the action of ES is 
concentration-dependent, with efficacy peaking at 
a certain dosage.18,19 There is thus an established 
need for a method of delivery, which can keep 
its concentration around the wound relatively 
constant.
 There are other problems concerning the 
use of live maggots for MDT. Repeated changes 
are necessary because the life cycles of larvae are 
relatively short. Moreover, their limited ‘shelf-life’ 
means that they need to be used soon after delivery. 
Smith et al22 recently experimented with a prototype 
hydrogel wound dressing containing L sericata larval 
ES. Their study on a wound model demonstrated a 
statistically significant difference between the ES-
impregnated hydrogel and the buffer-only control 
group; mean wound areas remaining after a 12-hour 
treatment were 40 vs 120 megapixels. These results 
indicated that the new delivery system could increase 
the wound healing rates in the experimental model.
Conclusions
Maggots have been used since antiquity to treat 
chronic wounds. With proper sterilisation and 
refinement of delivery techniques, they have proven 
to be a safe and effective method of debridement, 
for a variety of notoriously difficult-to-treat wounds. 
Although MDT is not without limitations, it remains 
a viable option for wounds or ulcers that fail to 
respond to conventional therapy. In Hong Kong, local 
experience of MDT is lacking with only individual 
cases reported.40 Although alternative methods 
such as ultrasound and waterjet debridement are 
available and yield results that are at least equivalent 
if not better than conventional therapy, whether MDT 
can be introduced for local patients will depend on 
the availability of sterile maggots. Use of maggots 
requires facilities to breed and produce them in 
sterile conditions. The therapy can then become 
both accessible and cost-effective. Overcoming 
political and administrative obstacles may also pose 
challenges, and include concerns with sterility and 
acceptance by nurses and patients. Meanwhile, 
new delivery systems may emerge and provide 
more promising, acceptable, and popular means of 
garnering the benefits of MDT.
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